Business Context and Reporting Period
Immunome, Inc. (IMNM) is a biotechnology company focused on developing targeted oncology therapies. The company operates as a non-accelerated filer, smaller reporting company, and emerging growth company. This Form 10-Q covers the quarterly period ended June 30, 2024. The company's pipeline includes one clinical asset, AL102 (a gamma secretase inhibitor in Phase 3 for desmoid tumors), and two preclinical assets: IM-1021 (an ROR1 antibody-drug conjugate) and IM-3050 (a FAP-targeted radioligand therapy).
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | As of June 30, 2024 |
|---|---|---|---|
| Collaboration Revenue | $2.4 million | $3.4 million | N/A |
| Total Operating Expenses | $42.4 million | $175.7 million | N/A |
| Net Loss | $(36.1) million | $(165.6) million | N/A |
| Net Loss Per Share (Basic & Diluted) | $(0.60) | $(2.97) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $165.3 million |
| Marketable Securities | N/A | N/A | $113.0 million |
| Total Assets | N/A | N/A | $296.2 million |
| Accumulated Deficit | N/A | N/A | $(388.4) million |
Material Changes vs. Prior Period
- Revenue Decline: Collaboration revenue decreased by $1.9 million (Q2) and $3.2 million (YTD) compared to the prior year periods, primarily due to reduced research and development activities allocated to the AbbVie collaboration.
- Significant Expense Increase: Operating expenses surged due to a one-time $118.3 million charge for in-process research and development (IPR&D) assets acquired from Zentalis, Ayala, and Atreca. These assets were expensed immediately as they had no alternative future use.
- Net Loss Expansion: The net loss widened significantly to $36.1 million for Q2 and $165.6 million for the six months ended June 30, 2024, compared to $5.6 million and $9.8 million in the respective prior year periods.
- Liquidity Improvement: Cash and cash equivalents increased from $98.7 million at year-end 2023 to $165.3 million, driven by a February 2024 follow-on public offering that generated $215.4 million in net proceeds.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($278.4 million total) to fund operations for at least 12 months from the filing date. Additional capital will be required for future development.
- Development Milestones:
- AL102: Enrollment for the Phase 3 RINGSIDE Part B trial was completed in February 2024. Topline data is expected in the second half of 2025.
- IM-1021 & IM-3050: The company expects to submit Investigational New Drug (IND) applications for both preclinical assets in the first quarter of 2025.
- Capital Markets: The company entered into an "at-the-market" (ATM) sales agreement in May 2024 to sell up to $200 million of common stock, though no shares have been sold under this agreement as of June 30, 2024.
- Risks: Key risks include the failure of clinical trials, inability to secure additional funding, reliance on third-party manufacturers, and the potential for significant dilution from future equity offerings. The company has a history of losses and expects to continue incurring significant losses.
Investor Verification Checklist
- IPR&D Accounting: Verify the rationale for expensing $118.3 million in acquired assets immediately rather than capitalizing them, and assess the impact on future earnings.
- Cash Runway: Confirm the 12-month liquidity projection given the high burn rate and the lack of product revenue.
- AL102 Trial Status: Monitor the timeline for the Phase 3 RINGSIDE Part B topline data (expected H2 2025) and any potential delays.
- Dilution Risk: Review the terms of the ATM agreement and the potential impact of future equity issuances on existing shareholders.
- Collaboration Revenue: Assess the sustainability of revenue from the AbbVie agreement as R&D activities fluctuate.